NanoVibronix announces UroShield health service study data published

NanoVibronix (NAOV) announced that an independent health service study of its UroShield is published in The Australian and New Zealand Continence Journal. The study highlights UroShield’s effectiveness in preventing catheter-associated urinary tract infections and recommends its adoption for appropriate patients with indwelling urinary catheters. Researchers found that patients using UroShield experienced an 86% reduction in UTI incidence; 70% reduction in catheter blockages; 82.8% less bladder irrigations performed and 52.3% less catheter changes. The clinicians reported improved overall catheter comfort and a reduction in the need for catheter-related interventions.